Shaw and Partners appointed as Lead Manager to the equity capital raising by Recce Pharmaceuticals News08 Oct 2019

Shaw and Partners has been appointed as Lead Manager to an equity capital raising by Recce Pharmaceuticals Limited (RCE).

 

RCE is undertaking a placement of approx. 15.5 million new securities to raise a minimum of $4 million. The company is reserving the right to accept oversubscriptions.

 

The offer price of $0.26 per security represents a 17.5% discount to last close of $0.315 as at 7 October 2019 and a 20.0% discount to a 15 day VWAP of $0.325 as at 7 October 2019.

 

The offer is available to Australian resident Sophisticated and Professional Investor clients only.

 

For more information please contact your Shaw and Partners Adviser.

 

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Wholly owned RECCE® antibiotics are unique; potency does not diminish even with repeated use, the common failure associated with existing antibiotics and their resulting emergence of resistant superbugs. Patented lead candidate RECCE® 327 has been developed for the treatment of blood infections and bacterial sepsis, affecting over 30 million people worldwide a year, growing at 8-13% per annum.

 

There are currently no drug therapies specifically for the treatment of severe sepsis and by far the most expensive condition treated in US hospitals. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post-approval. Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

Related Articles
News04 Aug 2020 Strandline Resources readies placement; Shaw and Partners on ticket.
Mineral sands explorer Strandline Resources was expected to press go on a capital raising on Tuesday morning.   Street Talk understands the $105 million company – which has proje... Read More
News30 Jul 2020 Adore Beauty hires banks for $600m-plus sharemarket float
Adore Beauty has chosen investment banks Morgan Stanley and UBS to spearhead its run at the ASX boards, and tapped Shaw and Partners as a co-lead manager.   As Street Talk reveal... Read More
News28 Jul 2020 E-commerce meets buy now, pay later in $200m IPO hopeful Zebit
ASX-aspirant Zebit will look to harness the momentum that's built behind e-commerce and buy now, pay later stocks through the pandemic, when it starts its run at the local bourse i... Read More
News27 Jul 2020 Shaw and Partners welcomes Garry Giblett and Brent Becroft to our office in Perth
Shaw and Partners is delighted to welcome Senior Investment Advisers Garry Giblett and Brent Becroft to our office in Perth.   Both Garry and Brent join Shaw and Partners Limited... Read More
A - Z  % Change  
{{data.Symbol}} {{data.CompanyName}} {{data.Close}} {{data.AsAt | date :'shortTime'}} {{data.Movement | number : 2}} {{data.MovementPercent | number: 2}}%